Previous close | 4.0332 |
Open | 3.4300 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.2600 - 4.0800 |
52-week range | 3.2400 - 11.0376 |
Volume | |
Avg. volume | 62,360 |
Market cap | 31.929M |
Beta (5Y monthly) | 1.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.9600 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, July 1,
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies for FSAD SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the o
Q1 2024 Dare Bioscience Inc Earnings Call